<DOC>
	<DOC>NCT00688103</DOC>
	<brief_summary>Multi-center, parallel-group, randomized, open control study. All patients will be selected to two treatment groups. 1. Etanercept alone treatment group (25mg, twice/week, s.c.) 2. Etanercept combined with MTX group (25mg, twice/week, s.c.+MTX 6-8mg/week)</brief_summary>
	<brief_title>Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients had to be at least 18 years of age fulfilled the 1987 revised classification criteria for RA by in American College of Rheumatology (ACR) met the guidelines for the proper use of ETN in Japan (having at least 6 tender joints and 6 swollen joints either serum Creactive protein more than 2 mg/dl or ESR no less than 28 mm at 1 hour, with adequate safety profiles) be ACR functional class IIII have been receiving MTX 6 mg/week for a minimum of 3 months at a stable dose for at least 4 weeks at the time of study enrollment Patients who required concurrent use of prednisone (PSL) &gt;10 mg/day, or its equivalent, were excluded from study entry the start of dose increment of PSL equivalents within 3 months of the study enrollment experience of antirheumatic therapy except for MTX and PSL equivalents previous treatment with ETN or any other biological treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>